Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
PaperCitations, authors & open-access status
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,977 citations, 2015 year and hybrid oa status.
1,977
Citations
2015
Year
hybrid
OA Status